

# Neutropenia Biologic Drug Treatment Companies Are Investing In Development Of Novel Drug Delivery Systems

*The Business Research Company's  
Neutropenia Biologic Drug Treatment  
Global Market Report 2021: COVID-19  
Growth And Change To 2030*


LONDON, GREATER LONDON, UK, May 18, 2021 /EINPresswire.com/ --

Companies in the [neutropenia biologic drug treatment market](#) are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug

delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

Other neutropenia biologic drug treatment market trends include mergers and acquisitions. In February 2018, Partner Therapeutics, a Boston-based cancer company, acquired Leukine (Sargramostim) from Sanofi for \$60 million. Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and it is indicated for the treatment of acute myelogenous leukemia (AML) in older adults both in allogeneic and autologous bone marrow transplantation. This acquisition provides a commercial business to Partner Therapeutics and also to make it a core component of the immune-oncology segment. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris.

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.



Read More On The Global Neutropenia Biologic Drug Treatment Market Report:

<https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatment-global-market-report-2020-30-covid-19-growth-and-change>

The global neutropenia biologic drug treatment market is expected to grow from \$11.55 billion in 2020 to \$12.19 billion in 2021 at a compound annual growth rate (CAGR) of 5.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The neutropenia biologic drug treatment market is expected to reach \$14.45 billion in 2025 at a CAGR of 4%.

The neutropenia biologic drug treatment market covered in this report is segmented by drug type into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim. The neutropenia biologic drug treatment market is also segmented by treatment type into antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others and by distribution channel into retail pharmacies, hospital pharmacies, online pharmacies.

Neutropenia Biologic Drug Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment global market overview, forecast neutropenia biologic drug treatment global market size and growth for the whole market, [neutropenia biologic drug treatment global market segments](#), and geographies, neutropenia biologic drug treatment global market trends, neutropenia biologic drug treatment market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Neutropenia Biologic Drug Treatment Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

G-CSF (Granulocyte Colony Stimulating Factors) Market - By Type (Pegfilgrastim, Filgrastim, Lenograstim, Others), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders, Others), And By Region, Opportunities And Strategies – Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market>

Blood Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report>

Anemia And Other Blood Disorder Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report>

Interested to know more about [The Business Research Company?](#)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/541332023>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.